Cost of managing patients with venous leg ulcers

Ceri J. Phillips | Ioan Humphreys | Dan Thayer | Muhammad Elmessary | Huw Collins | Chris Roberts | Gurudutt Naik | Keith Harding

1College of Human and Health Sciences, Swansea University, Swansea, UK
2SAIL Databank: School of Medicine, Swansea University, Swansea, UK
3Clinical Resolutions, Hessle, UK
4Welsh Wound Innovation Centre, Cardiff University, Cardiff, UK

Correspondence
Ioan Humphreys, MSc, College of Human and Health Sciences, Swansea University, Swansea, UK.
Email: i.humphreys@swansea.ac.uk

Funding information
Medical Ethics Pty, Melbourne Australia

Abstract
The aim of this study was to estimate costs associated with the management of patients with venous leg ulcers (VLUs) from the perspective of the UK National Health Service (NHS). The analysis was undertaken through the Secure Anonymised Information Linkage Databank which brings together and anonymously links a wide range of person-based data from around 75% of general practitioner (GP) practices within Wales (population coverage ~2.5 million). The data covered an 11-year period from 2007 to 2017. All patients linked to the relevant codes were tracked through primary care settings, recording the number of GP practice visits (number of days with an event recorded), and wound treatment utilisation (eg, dressings, bandages, etc.) Resources were valued in monetary terms (£ sterling) and the costs were determined from national published sources of unit costs. This is the first attempt to estimate the costs of managing of VLUs using routine data sources. The direct costs to the Welsh NHS are considerable and represent 1.2% of the annual budget. Nurse visits are the main cost driver with annual estimates of £67.8 million. At a UK level, these costs amount to £1.98 billion. Dressings and compression bandages are also major cost drivers with annual Welsh estimates of £828 790. The direct cost of managing patients with VLUs is £7706 per patient per annum, which translates to an annual cost of over £2 billion, when extrapolated to the UK population. The primary cost driver is the number of district nurse visits. Initiatives to reduce healing times through improving accuracy of initial diagnosis, and improved evidence-based treatment pathways would result in major financial savings.

Keywords
chronic wounds, economic burden, linked routine data, VLUs
INTRODUCTION AND BACKGROUND

Chronic venous insufficiency is the most common cause of leg ulceration, in the community. Major implicating factors for venous leg ulcers (VLUs) include family history, obesity, deep venous thrombosis, and increasing age. It is estimated that VLUs affect up to 3% of the adult population worldwide and are a major cause of morbidity and decreased health-related quality of life. Chronic venous insufficiency is often not diagnosed until LUs develop, at which stage its treatment can be difficult and often leads to patients experiencing a repeated pattern of ulceration, healing and recurrence. The main stay of treatment for venous insufficiency includes the use of compression bandages to apply external pressure to the lower limbs with the aim of improving venous function. Despite appropriate treatment, the majority of VLUs take several weeks, even months to heal, and patients can have high levels of exudate and odour. This can impact severely on the patients' quality of life and also lead to other psychological issues such as anxiety, depression, and social exclusion. The current health-related burden of VLUs is imprecise and has been the subject of several studies that have attempted to estimate, not only the health impact on the patient, but also the economic burden. Annual costs of treating patients with leg ulcers (LU) in the UK have been estimated to be £1.938 billion.

A second study estimated the cost of managing an unhealed VLU to be four to five times more than that of managing a healed VLU (£3000 per healed VLU vs £13,500 per unhealed VLU). Finally, the latest study by Guest et al reported the annual cost of treating patients with LU in the UK to be £1.94 billion. A second study estimated the cost of managing an unhealed VLU to be four to five times more than that of managing a healed VLU (£3000 per healed VLU vs £13,500 per unhealed VLU).12 The approach taken by this study differs in the methodology used by Guest et al. The Secure Anonymised Information Linkage (SAIL) Databank was interrogated (~2.5 million people) over a period of 11 years, whereas the previous study used a total of 505 patients with VLUs evaluated over a 12-month period.

Aims and objectives

The aim of this study was therefore to estimate the costs associated with the management of patients with VLUs from the perspective of the UK National Health Service (NHS) using routine data as provided in the SAIL database. Specific objectives of the study were to:

- Establish a profile of patients with VLUs, based on clinical coding.

Methods

The analysis was undertaken through the SAIL Databank, which brings together, and anonymously links, a wide range of person-based data from around 75% of general practitioner (GP) practices within Wales (population coverage ~2.5 million people). It includes GP records, outpatient (OP) clinical data, inpatient...
(IP) episodes, and accident and emergency (A&E) Department data, to create an encrypted anonymised linking field for each individual. This linkage allows the patient pathway to be tracked through the NHS Wales system both retrospectively and prospectively from a specific reference point. The patient cohort was identified through relevant clinical codes, and the resource implications of their management were collected and estimated using published sources.16,17

This approach provided an in-depth inventory of the contacts, consultations, and resources utilised in the current management of such patients, enabling the potential implications of adjustments to these management approaches.

1.3 | Data analysis

The SAIL database was interrogated to catalogue health service resource utilisation by this cohort of patients. We used the GP Data to identify and quantify all events in order to measure service usage.

The Welsh Demographic Service Data18 was utilised to gather basic demographics, information on follow-up time (residency in Wales and GP registrations), and Welsh Index of Multiple Deprivation19 score to measure deprivation.

1.4 | Resource use

All patients linked to the relevant codes were tracked through primary care settings, recording their level of GP practice visits (number of days with an event recorded) and wound treatment utilisation (eg, dressings, bandages, etc.). District nurse visits were not available in the data, so the extent of district nurse time involved in the management of the VLU wounds was estimated as two visits per week. This estimate was based on detailed discussions with several clinicians and a tissue viability nurse.

1.5 | Cost data

Resources were valued in monetary terms (£ sterling) and the costs determined from national published sources of unit costs including the British National Formulary (BNF)16 and Personal and Social Services Research Unit (PSSRU) unit costs,17 where costs were unavailable and/or local costs were utilised (eg, from local financial records or NHS Wales formulary); these were provided by other sources. The currency year was 2018, while an inflation calculator (Bank of England) was used to convert previous years’ costs to current prices (Table 1).

1.6 | Perspective

The perspective taken was that of the UK NHS.

1.7 | Statistical analysis

Statistical analysis was undertaken in SPSS Version 25 for Windows. Furthermore, basic descriptive demographic statistics were also collected alongside the resource use and cost data. Survival analysis of treatment duration was conducted using R 3.5.

2 | RESULTS

The report utilised primary care data from the SAIL Databank, covering approximately 75% of GP practices in Wales. The study period was between 2007 and 2017.

A VLU was defined as either a specific code that implies a VLU, or the combination of a non-specific ulcer code with a code for either compression stockings or varicose veins. Non-specific codes included codes such as “recurrent LU” (M274.), “non-healing LU” (M273.), and “traumatic LU” (M2716), where a combination of codes was used:

- For the combination of ulcer code and varicose veins, there was no time restriction: each code could appear anywhere within the study period.

| Health service resource | Unit cost (£) | Source |
|-------------------------|--------------|--------|
| GP surgery visit (per surgery consultation lasting 9.22 min) | £38 | PSSRU 2018 |
| GP home visit | £120 | PSSRU 2013 (inflated to 2018 prices using BOE calculator) |
| Practice nurse | £42 | PSSRU 2018 |
| GP telephone triage | £14.80 | PSSRU 2018 |
| Practice nurse telephone triage | £7.70 | PSSRU 2018 |
| District nurse | £78 | PSSRU 2015 (inflated to 2018 prices using BOE calculator) |
| Dressings, bandages, medication, etc. | Various | BNF (2018) |

Abbreviations: BNF, British National Formulary; BOE, Bank of England; PSSRU, Personal and Social Services Research Unit.
• For the combination of an ulcer code and a stocking, the ulcer diagnosis code was required to come first.

The date of diagnosis with VLU was the first occurrence of a VLU code (either specific or non-specific) (Table 2).

### 2.1 Cohort demographics

Of the cohort of 8352, 56% (n = 4,648) were female and 44% male (n = 3,704). The average age of females was 74.8 and 68.4 years for males.

### 2.2 Treatment

Read codes in the GP data only show the occurrence of a prescription. They do not show the quantity or dose, so the counts shown represent number of prescriptions (each of which may be for multiple items).

The cost of all the treatments (dressings, bandages, compression stockings, etc.) over the 11 years linked to the VLU-related codes (n = 8352) was costed (taking into account multiple items) using the BNF and GP Prescription data from Primary Services Wales, where the average number of items per prescription per patient was estimated (Table 3).

Table 4 summarises the costs of all the treatment types. The main cost drivers were “Compression Other” (£1,754,951) and “Dressing” (£6,157,949).

### 2.3 Cost of GP event days

Not all days with an event represent consultations with a GP. Some are prescription renewals, receipt of letters from hospital, and other activities. There is no reliable way from the data held in SAIL to identify the number of patient consultations. The assumption was made that 33% of all days with an event recorded represented a consultation. This estimate was based on discussions with several clinicians and a GP. This is probably a conservative assumption, because it results in consultation rates per person-year that are lower than previously published rates for the UK while the cohort in this study is older and is known to have health issues requiring a high level of care. Therefore, a pragmatic approach to defining and costing a GP contact was taken.

| **TABLE 2** Cohort characteristics |
|------------------|-----|
| **Read code**    | **n** |
| A specific venous leg ulcer (VLU) code (M2714 and M2715) | 1828 |
| A non-specific VLU code combined with compression stocking | 3104 |
| A non-specific VLU code combined with varicose veins | 3420 |
| **Total**        | **8352** |

| **TABLE 3** Events by treatment type (2007-2017) |
|------------------|-----|-----|-----|-----|
| **Treatment**    | **Patients** | **Event/prescription count** | **Avg. per patient** | **Sum (£)** |
| Hydrocellular foam | 107  | 277 | 2.6 | £19 932 |
| Hydrofiber Ribbon  | 365  | 1269 | 3.5 | £25 856 |
| Barrier Cream     | 874  | 4393 | 5.0 | £15 100 |
| Barrier Spray     | 540  | 1824 | 3.4 | £17 071 |
| Compression Applicator | 1047 | 1267 | 1.2 | £35 355 |
| Compression Other | 3906 | 61 693 | 15.8 | £1 754 951 |
| Compression Stocking | 3607 | 14 741 | 4.1 | £585 803 |
| Autolytic hydrogels | 1104 | 3782 | 3.4 | £134 663 |
| Autolytic Manuka Honey | 1107 | 3037 | 2.7 | £64 606 |
| Dressing          | 7002 | 193 161 | 27.6 | £6 157 950 |
| Gauze             | 1306 | 7306 | 5.6 | £27 320 |
| Line              | 2827 | 23 211 | 8.2 | £83 757 |
| Swab              | 180  | 573  | 3.2 | £21 645 |
| Swab              | 363  | 1909 | 5.3 | £9306 |
| Elasticated tubular support bandage | 1457 | 9414 | 6.5 | £17 851 |
| **Total**         | **25 792** | **327 857** | **12.7** | **£8 971 166** |
taken, assuming that 82% of consultations were conducted at the surgery, 12% of consultations were over the telephone, and 3% were either home visits or conducted at other locations. For ease of analysis and to combat the unknown quantity of “other locations,” the 3% conducted at other locations were added into the telephone consultations to make them 15% of the 82%.

Additionally, the study disaggregated the numbers further, by assuming that 62% of the above-mentioned consultations were undertaken by GPs. Thirty-four percentage were undertaken by practice nurses and 4% by other clinicians. Again, for ease of analysis and the unknown quantity of “other clinicians,” the 4% other clinicians were classed as being undertaken by practice nurses (Table 5).

| Group                  | N  | Mean (SD)     | Sum        |
|------------------------|----|---------------|------------|
| Hydrocellular foam     | 7  | £2847 (£5002) | £19 932    |
| Hydrofiber Ribbon      | 4  | £6464 (£6309) | £25 856    |
| Barrier Cream          | 9  | £1678 (£3329) | £15 100    |
| Barrier Spray          | 2  | £8536 (£11 646) | £17 072   |
| Compression Applicator | 3  | £11 785 (£16 616) | £35 355  |
| Compression Other      | 116| £15 129 (£94 110) | £1 754 951|
| Compression Stocking   | 93 | £6299 (£23 228) | £585 803  |
| Autolytic Hydrogels    | 21 | £6413 (£16 106) | £134 663  |
| Autolytic Manuka Honey | 30 | £2154 (£4982)  | £64 606   |
| Mechanical Debridement | 2  | £48 708 (£68 031) | £97 415   |
| Passive Debridement    | 7  | £5923 (£12 085) | £41 461   |
| Sharp Debridement      | 11 | £604 (£925)   | £6647     |
| Dressing               | 912| £6752 (£33 333) | £6 157 949|
| Gauze                  | 5  | £5464 (£5649)  | £27 320   |
| Line                   | 54 | £1551 (£4321)  | £83 757   |
| Swab type one          | 2  | £10 823 (£10 448) | £21 645   |
| Swab type two          | 2  | £4653 (£1700)  | £9306     |
| Elasticated tubular support bandage | 12 | £1488 (£2436) | £17 850   |

| Total                  | 1292| £6136 (£23 350) | £9 116 690|

| Year | Days with an event | Estimated consultations | Patient count | Avg. per patient | GP cost | Nurse cost | Total cost |
|------|--------------------|-------------------------|---------------|------------------|---------|------------|------------|
| 2007 | 12 357             | 4119                    | 1021          | 4.0              | £94 439 | £59 705    | £154 144   |
| 2008 | 23 572             | 7857                    | 1709          | 4.6              | £180 150 | £113 893   | £294 043   |
| 2009 | 29 279             | 9760                    | 2204          | 4.4              | £223 766 | £141 467   | £365 233   |
| 2010 | 34 716             | 11 572                  | 2506          | 4.6              | £265 318 | £167 737   | £433 055   |
| 2011 | 38 903             | 12 968                  | 2760          | 4.7              | £297 317 | £187 968   | £485 285   |
| 2012 | 37 227             | 12 409                  | 2929          | 4.2              | £284 509 | £179 870   | £464 378   |
| 2013 | 38 201             | 12 734                  | 3173          | 4.0              | £291 952 | £184 576   | £476 528   |
| 2014 | 40 952             | 13 651                  | 3283          | 4.2              | £312 977 | £197 868   | £510 845   |
| 2015 | 40 047             | 13 349                  | 3405          | 3.9              | £306 061 | £193 495   | £499 556   |
| 2016 | 34 783             | 11 594                  | 3326          | 3.5              | £265 830 | £168 061   | £433 891   |
| 2017 | 28 207             | 9402                    | 3186          | 3.0              | £215 573 | £136 288   | £351 861   |
| Total| 358 244            | 119 415                 | 29 502        | 4.0              | £2 737 892 | £1 730 928 | £4 468 819 |
Table 6: Summary table of all treatment and visit costs

| Overall summary of VLU-related treatment and resource use costs |  |
|---|---|
| SAIL observed |  |
| 8352 | No. of patients |
| £4,468,819 | GP events/contacts |
| £9,116,689 | Treatments |
| £745,265,664 | DN visits (based on 2 per week) |
| £758,851,172 | Total over 11 years |
| £68,986,470 | Estimated annual cost of treatment (n = 8352) |
| Wales |  |
| 11,136 | No. of patients |
| £6,586,024 | GP events/contacts |
| £11,395,861 | Treatments |
| £993,687,552 | DN visits (based on 2 per week) |
| £1,010,669,437 | Total over 11 years |
| £91,879,040 | Estimated annual cost of treatment (n = 11,136) |
| UK |  |
| 244,992 | No. of patients |
| £10,892,747 | GP events/contacts |
| £16,412,092 | Treatments |
| £21,888,430,983 | DN visits (based on 2 per week) |
| £21,888,430,983 | Total over 11 years |
| £19,879,040 | Estimated annual cost of treatment (n = 244,992) |

Abbreviations: DN, district nurse; GP, general practitioner; SAIL, Secure Anonymised Information Linkage.

The unit costs for health care utilisation were obtained from a number of PSSRU sources17,23 and are shown in Table 1.

2.4 Total resource utilisation

Table 6 summarises all the costs relating to VLU treatment observed via the GP data within the SAIL Databank over the 11 years. Furthermore, the “observed” data has been extrapolated to all-Wales and UK populations. This results in an estimated annual cost of treating VLUs of £68,986,470 for the “observed” data or £8,260 per patient annually for the cohort based on UK prevalence.

When resource use is compared with prescription use, there were 2.7 times as many prescriptions as there were estimated consultations—that is, 321,038/119,415. The cost of prescribed treatments was roughly twice the cost of consultations—that is, £9,116,690/£4,468,819.

3 Discussion

This is the first to attempt to estimate the economic burden of VLUs using the SAIL Databank. The direct costs to the Welsh NHS are considerable and represent 1.2% of the annual budget. District Nurse visits are the main cost driver, with annual estimates of £67,751,424. At a UK level, these costs amount to £1,987,375,104. Dressings and compression bandages are also significant cost drivers with annual Welsh estimates of £8,771,897. In terms of the SAIL estimates, this represents 12.6% of the total treatment budget. An earlier study using the SAIL data base showed that 3% of spend for all wounds in primary care was directed at the costs of dressings.24 This difference could be due to the increase in SAIL Databank coverage since the publication of that study (45% Vs 75%), and also the use in this study of a more sophisticated and sensitive linkage algorithm. When resource use is compared with prescription use, the percentage use of prescriptions per resource used (ie, GP or nurse consultation) is 2.7 prescriptions per patient—that is, 321,038/119,415. When the costs are compared, the average prescription cost is £2 per patient—that is, £9,116,690/£4,468,819.

The estimates presented in this study are generally comparable to Guest et al’s 2017 paper where annual English NHS costs are estimated to be £1.3 billion.

The results confirm other findings associated with the cost of wound care. It is mistakenly believed that the use of wound management materials per se is the major cost driver in treatment costs, whereas in reality, nursing time and hospital costs are together responsible for the around 80% and 85% of the total cost.25 Healing times, frequency of dressing changes, and complications are three important drivers of cost.

Previous authors have also demonstrated that the management and treatment of chronic venous ulcers add substantial costs to global health care systems, as well as having a negative impact on patient’s quality of life.12 The results of this study have also demonstrated that treating VLUs consumes large amounts of medical products, drugs, and compression bandaging. In terms of health care clinical practitioners treating this condition, the application of compression bandaging, an essential component of treatment, is known to be variable.26 Furthermore, the plethora of available wound dressings, with varying evidence relating to their effectiveness, also pose challenges in developing individual care pathways.

There is increasing evidence that there is significant sub-optimal service delivery in relation to wound management, and which is not based on notions of best practice. These include inadequate diagnosis, failure to identify the wound type, not using best practice for managing the underlying pathology, and the lack of adequate health professional education and training.27
 Possibly, the best way of attacking these particular challenges is looking at reducing waste, harm, and variation in practice and ensuring that there are local, regional, national, and international guidelines, protocols, algorithms, and care pathways that should be followed, wherever possible, for the vast majority of patients. In addition, the continued creation of local, regional, and national centres of excellence, where patients with complex LUs could be assessed and their wounds resolved would be of great benefit.

Innovative medical approaches are evolving that will provide additional alternatives and additions to current practices to heal VLUs faster, and have the potential to significantly reduce the total cost of treatment of such wounds. Two illustrative examples will be discussed. Although compression therapy improves venous ulcer healing, it does not treat the underlying causes of venous hypertension. Treatment of superficial venous reflux has been shown to reduce the rate of ulcer recurrence, but the effect of early endovenous ablation of superficial venous reflux on ulcer healing remains unclear. In a large randomised study, 450 patients undergoing early endovenous ablation of superficial venous reflux with compression resulted in faster healing of venous ulcers and more free from ulcers than ulcers treated with compression and deferred venous ablation. A second example of innovation that could potentially help to speed up ulcer healing is the use of topical multimodal anaesthesia combined with adrenaline and an antimicrobial prior to and post-wound debridement. Ensuring confidence in the attending clinician to debride and giving the patient a pain-free experience while optimising wound bed preparation will lead to successful outcomes. If wound bed preparation is optimised early in the treatment pathway faster healing may occur. The potential clinical and economic benefits of topical multimodal anaesthesia as part of achieving pain relief during debridement have been summarised in a recent publication. It is recommended that better education of debridement types in the curriculum for nurses at University undergraduate level would also help tackle the issue of choosing the appropriate debridement techniques in practice. This would also help address the issue of whether the right professionals are debriding at the right time, in the right manner, and in the right context.

Although clinical coding may be an issue, we have tried to improve the quality of data using the more accurate prescription data to qualify the picked up clinical codes.

The results of the study provide an important reference point for policy makers inconcerting resources and strategies in tackling the main cost drivers for this condition. While it is the ideal in aiming complete healing of ulcers, this is not always possible. To improve resource efficiency, strategies/treatments that effectively reduce clinician/district visits should be used.

Secondary care data have not been included due to the difficulty in identifying what care is driven by VLUs. The national out-patient data in Wales do not contain information on diagnoses and treatments. Further research is needed to investigate the coding structure of these events within SAIL and how best to tackle the issues without having to make too many assumptions. Inpatient stays are also missing from this analysis due to a similar coding problem. However, as the treatment of VLUs is likely to take place in primary community care by practice nurses and district nurses, the assumption was made that there would be an insignificant level of VLU-related inpatient activity.

The coding issues relating to GP events/contacts are another limitation which were addressed in the assumptions made. However, by using the existing evidence laid out by Hippsley-Cox (2009), a reasonable assumption was made of the types of contact that patients would have with either the GP or the practice nurse.

The estimate of two district nurse visits per week may be an underestimate of the actual “real-world” frequency of visits by these practitioners to change dressings, bandages, etc. If the average number of district nurse visits were increased to three, then the observed SAIL estimate of annual costs would be £102,862,182 or £12,316 per patient. Being able to accurately identify district nurse visits within the SAIL databank would be advantageous for future wound-related routine data research.

We recognise that the relatively narrow perspective of the Welsh NHS is a limitation. However, we believe it still to be reflective of the UK NHS as a whole.

Additionally, we have not costed other health-related costs, such as the use of other medications such as pain killers, antibiotics, etc.

Finally, the relatively narrow perspective of Welsh NHS costs shows just one picture of the economic burden VLUs have on the UK health care system. A wider, more societal perspective would shed light on further substantial costs relating to caregivers, loss of productivity, and health-related quality of life.

### 3.1 Strengths and limitations

SAIL data base that covers nearly 70% to 80% of welsh population was used and extrapolations made from this represent a more realistic estimate of the problem.
4 | CONCLUSION

The direct Welsh NHS costs of relating to the managing patients with treatment of VLUs is £7,706 per patient per annum, which translates to an annual cost of over £2 billion, when extrapolated to the UK population. The primary cost driver is the number of district nurse visits. Future initiatives to reduce healing times, through improving accuracy of initial diagnosis, and improved evidence-based treatment pathways would result in major financial savings.

ACKNOWLEDGEMENTS

The authors would also like to acknowledge the help of Trudi Young and Dr Melanie Thomas in the development of this analysis and Medical Ethics Pty, Melbourne, Australia, for the provision of a research grant to allow this work to be completed. This study was commissioned and funded by the Medical Ethics Pty, Melbourne, Australia.

CONFLICT OF INTEREST

The study's sponsors had no involvement in the study design; the collection, analysis, and interpretation of the data and methodology; the writing of this manuscript; and the decision to submit this article for publication. The views expressed in this article are those of the authors and not necessarily those of the sponsors. The authors have no conflicts of interest with this study.

ORCID

Ioan Humphreys @ https://orcid.org/0000-0001-7993-0179

REFERENCES

1. Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg. 1994;81:182-187.
2. Sadler GM, Russell GM, Boldy DP, Stacey MC. General practitioners' experiences of managing patients with chronic leg ulceration. Med J Aust. 2006;185:78-81.
3. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488-498. https://doi.org/10.1056/NEJMra055289.
4. Margolis DJ, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol. 2002;46:381-6.3.
5. White JV, Ryjewski C. Chronic venous insufficiency. Perspect Vasc Surg Endovas Ther. 2005;17:319-27.2.
6. Couzan S, Leizorovicz A, Laporte S, et al. A randomized double-blind trial of upward progressive versus degressive compressive stockings in patients with moderate to severe chronic venous insufficiency. J Vasc Surg. 2012;56:1344e1-50e1. https://doi.org/10.1016/j.jvs.2012.02.060.5.
7. Pfisterer L, Konig G, Hecker M, Korff T. Pathogenesis of varicose veins—lessons from biomechanics. Biomech varicosis. 2014;43:88-99. https://doi.org/10.1024/0301-1526/a000335.6.
8. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15:175-184. https://doi.org/10.1016/j.annepidem.2004.05.015.
9. Green J, Jester R. Health-related quality of life and chronic venous leg ulceration: Part 2. Br J Community Nurs. 2010;15: S4-S6. https://doi.org/10.12968/bjcn.2010.15.Sup1.46906.
10. Maddox D. Effects of venous leg ulceration on patients’ quality of life. Nurs Stand. 2012;26:42-49. https://doi.org/10.7748/ns2012.05.26.38.42.c9111.
11. Guest JF, Vowden K, Vowden P. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. J Wound Care. 2017;26:292-303. https://doi.org/10.12968/jowc.2017.26.6.292.
12. Guest JF, Fuller GW, Vowden P. Venous leg ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018;15(1):29-37. https://doi.org/10.1111/iwj.12814.
13. SAIL Databank. https://saildatabank.com/ (accessed October 2018).
14. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak. 2009;9:3. http://www.ncbi.nlm.nih.gov/pubmed/19149883.
15. Ford DV, Jones KH, Verplancke JP, et al. The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Services Res. 2009;9:157 http://www.ncbi.nlm.nih.gov/pubmed/19732426.
16. British National Formulary (BNF). https://bnf.nice.org.uk/. Accessed October 2018.
17. Personal Social Service Research Unit (PSSRU). http://www.pssru.ac.uk/project-pages/unit-costs/2017/. Accessed October 2018.
18. NHS Wales Informatics Service. http://www.wales.nhs.uk/nwis/page/52552. Accessed October 2018.
19. Welsh Government (Statistics). https://gov.wales/statistics-and-research/welsh-index-multiple-deprivation/?lang=en. Accessed October 2018.
20. Primary Care Services Wales NHS. http://www.primarycareservices.wales.nhs.uk/general-practice-prescribing-data-extract. Accessed October 2018.
21. Hobbs DR, Bankhead C, Mukhtar T, et al. Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet. 2016;387:2323-2330. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00620-6/fulltext.
22. Hippisley-Cox J, Vinogradova Y. Trends in Consultation Rates in General Practice 1995/1996 to 2008/2009. Analysis of the QResearch database. http://citeseerx.ist.psu.edu/viewdoc/download;doi=10.1.1.518.744&rep=rep1&type=pdf
23. Personal Social Service Research Unit (PSSRU). 2015. http://www.pssru.ac.uk/project-pages/unit-costs/2015/. Accessed October 2018.
24. Phillips CJ, Humphreys I, Fletcher J, et al. Costs associated with the management of patients with chronic wounds using linked routine data. Int Wound J. 2016;13(6):1193-1197.
25. Lindholm C, Searle R. Wound management for the 21st century: combining effectiveness and efficiency. Int Wound J. 2016;13:5-15. https://doi.org/10.1111/iwj.12623.
26. Moffatt CJ, Edwards L, Collier M, et al. A randomised controlled 8 week cross-over clinical evaluation of the 3M Coban 2 layer compression system versus Profore to evaluate product performance in patients with venous leg ulcers. *Int Wound J*. 2008;5(2):267-279.

27. Aitkin L, Bucko C, Montero C, et al. Implementing TIMERS; the race against hard to heal wounds. *J Wound Care*. 2019;28(3 Suppl):S1-S49.

28. Gohel M, Heatley F, Liu X, et al. A randomised trial of early endovenous ablation in venous ulceration. *New Eng J Med*. 2018;378:2105-2114.

29. Roberts CD, Windsor PA. Innovative pain management solutions in animals may provide improved wound pain reduction during debridement in humans: an opinion informed by veterinary literature. *Int Wound J*. 2019;16(4):968-973. https://doi.org/10.1111/iwj.13129.